Therapeutic Approach | Program | Class | Indication | Lead Discovery | Lead Optimization | Pre-clinical in vivo efficacy | IND enabling studies |
---|---|---|---|---|---|---|---|
Tumor Associated Proximity Antigen (TAPA) | |||||||
IDP-001 | TAPA-ADC | Oncology Multiple Cancers | |||||
IDP-001 | TAPA-TCE | Oncology Multiple Cancers | |||||
Synapse Modulation | |||||||
IDP-002 | Sequestration | Immuno-Oncology | |||||
IDP-003 | Recruitment |
Autoimmune disease | |||||
Discovery | |||||||
Discovery | Multiple | Several |
Tumor Associated Proximity Antigen (TAPA) | |||
---|---|---|---|
Lead Discovery | Lead Optimization | Pre-clinical in vivo efficacy | IND enabling studies |
IDP-001 Class: TAPA-ADC Indication: Oncology Multiple Cancers | |||
IDP-001 Class: TAPA-TCE Indication: Oncology Multiple Cancers | |||
Synapse Modulation | |||
Lead Discovery | Lead Optimization | Pre-clinical in vivo efficacy | IND enabling studies |
IDP-002 Class: Sequestration Indication: Immuno-Oncology | |||
IDP-003 Class: Recruitment Indication: Autoimmune disease | |||
Discovery | |||
Lead Discovery | Lead Optimization | Pre-clinical in vivo efficacy | IND enabling studies |
Discovery Class: Multiple Indication: Several | |||